Trial Profile
A Phase I Open-Label Study to Assess the Safety and Tolerability of KU-0059436 in Combination With Carboplatin KU-0059436 in Combination With a Paclitaxel/Carboplatin T/C Doublet and KU-0059436 in Combination With Paclitaxel in the Treatment of Patients With Advanced Solid Tumours
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 19 Jan 2024
Price :
$35
*
At a glance
- Drugs Olaparib (Primary) ; Carboplatin; Paclitaxel
- Indications Advanced breast cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 15 Jan 2024 Planned End Date changed from 29 Dec 2023 to 31 Dec 2024.
- 19 Dec 2022 Planned End Date changed from 30 Dec 2022 to 29 Dec 2023.
- 22 Nov 2021 Planned End Date changed from 31 Dec 2021 to 30 Dec 2022.